UCB Pharma

vorige Seite Seite 1 von 2 nächste Seite

UCB Full Year Report 2020: UCB - sustaining growth, now and into the future

· Revenue increased to EUR 5.3 billion (+9%, +8% CER[1]) net sales to EUR 5.1 billion (+8%, +7% CER)

25.02.2021 07:00

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

* Through this collaboration with Microsoft, UCB seeks to discover and develop medicines faster for people living with severe diseases in immunology and neurology

23.02.2021 07:00

Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases

- Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis

09.09.2020 08:35

Final Phase II Results for UCB's Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

- Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration

09.09.2020 07:01

UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease

- UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment

29.07.2020 08:31

UCB Half Year Report 2020

- UCB's resilient product portfolio drives continued company growth

27.07.2020 07:10

UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

* Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active …

05.06.2020 07:25

UCB's General Meeting of Shareholders

* Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020

10.04.2020 15:01

UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

- The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently …

02.04.2020 15:35

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, …

10.12.2019 01:46

UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's …

10.10.2019 09:38

Experts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today

A new European survey, released today by UCB, reveals that bone specialists believe osteoporosis and fragility fractures are neglected and under prioritized by their healthcare systems, and action needs to …

20.09.2019 17:10

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

* Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints

18.10.2018 07:01

UCB Announces Approval of NEUPRO® in China to Treat Parkinson's Disease

* NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without levodopa) or in combination with levodopa

02.07.2018 18:31
vorige Seite nächste Seite